|
Market Cap (2-Jul) $176,237,888 (1,192nd) |
Close (28-Sep) $0.205 |
Volume (28-Sep) 0 |
Shortsold (21-Sep) 297,501 (0.03%) (573rd) |
|
52w High $0.000 |
52w Low $0.000 |
P/E - |
EPS -0.009 |
RAP released this announcement to the ASX on 10 February 2021, 8:58. The announcement is marked as price sensitive, and is 2 page(s) in length and 99.76kb in size.
You can view all announcements from RAP and see how they appear on a price chart on the announcements page.
At the date of this announcement, RAP was 0.164% short sold according to ASIC data. It was ranked the 380th most shorted stock on the ASX. It remains ranked 573rd as of the latest reported data (21 September 2022).
| Other Recent Announcements from RAP | |
|---|---|
| Removal from Official List | 27 September 2022, 11:58 |
| Scheme of Arrangement has been Implemented | 26 September 2022, 16:28 |
| Ceasing to be a substantial holder | 20 September 2022, 8:09 |
| Pre-Submission package lodged with the US FDA | 10 February 2021, 8:58 |
| ResApp receives $801,738 R&D tax incentive refund and grant | 4 February 2021, 9:09 |
| ResApp strengthens patent position in Europe | 2 February 2021, 8:59 |
| Quarterly Activities Report and Appendix 4C | 29 January 2021, 9:17 |
You must be logged in to post a reply.
ResApp Health 